# EDGAR Filing Document

**Accession Number:** 0002050902
**File Stem:** 0001193125-25-330843
**Filing Date:** 2025-12
**Character Count:** 20345
**Document Hash:** aa706d0e40d8439f4a7a3c290e7fb391
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-330843.hdr.sgml**: 20251223

**ACCESSION NUMBER**: 0001193125-25-330843

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251223

**DATE AS OF CHANGE**: 20251223

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vor Biopharma Inc.
- **CENTRAL INDEX KEY:** 0001817229
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 811591163
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92269
- **FILM NUMBER:** 251600478

**BUSINESS ADDRESS:**
- **STREET 1:** 500 BOYLSTON STREET
- **STREET 2:** SUITE 1350
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
- **BUSINESS PHONE:** 617-655-6580

**MAIL ADDRESS:**
- **STREET 1:** 500 BOYLSTON STREET
- **STREET 2:** SUITE 1350
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ForGrowth III PA B.V.
- **CENTRAL INDEX KEY:** 0002050902

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **STREET 1:** FORBION CAPITAL PARTNERS
- **STREET 2:** GOOIMEER 2-35
- **CITY:** NAARDEN
- **STATE:** P7
- **ZIP:** 1411
- **BUSINESS PHONE:** 31 356993000

**MAIL ADDRESS:**
- **STREET 1:** FORBION CAPITAL PARTNERS
- **STREET 2:** GOOIMEER 2-35
- **CITY:** NAARDEN
- **STATE:** P7
- **ZIP:** 1411

### Attached PDF Documents

**Attachment 1:** `ck0000000000-ex99_1.pdf`

_No text found in this document._

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**VOR BIOPHARMA INC.**

*(Name of Issuer)*

**Common Stock, $0.0001 par value per share**

*(Title of Class of Securities)*

**929033207**

*(CUSIP Number)*

**Forbion Capital Partners**<br>Gooimeer 2-35<br>Naarden P7 1411 DC<br>31 (0) 35 699 30 00

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**12/18/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **929033207** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**ForGrowth III PA B.V.** | Name of reporting person<br>**ForGrowth III PA B.V.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**P7** | Citizenship or place of organization<br>**P7** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**10237714.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**10237714.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**10237714.00** | Aggregate amount beneficially owned by each reporting person<br>**10237714.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.99%** | Percent of class represented by amount in Row (11)<br>**9.99%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** The reported share amounts consist of (i) 3,617,354 shares of Common Stock and (ii) 6,620,360 shares of Common Stock underlying pre-funded warrants (the "Pre-Funded Warrants").  Exercisability of the Pre-Funded Warrants is subject to a beneficial ownership limitation of 9.99% of the number of shares of Common Stock to be outstanding immediately after giving effect to the issuance of the shares issuable upon exercise (the "Beneficial Ownership Limitation"). The percentage set forth in Row 13 gives effect to such Beneficial Ownership Limitation, but the number of shares reported in Rows 8, 10 and 12 includes the full number of shares of Common Stock underlying the Pre-Funded Warrants and does not give effect to the Beneficial Ownership Limitation.  As such, some of the Pre-Funded Warrants are not presently exercisable due to the Beneficial Ownership Limitation, and the actual number of shares of Common Stock beneficially owned by the Reporting Persons is less than the number of shares of Common Stock of the Issuer reported herein.

| **CUSIP No.** | **929033207** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Forbion Growth Opportunities Fund III Cooperatief U.A.** | Name of reporting person<br>**Forbion Growth Opportunities Fund III Cooperatief U.A.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**P7** | Citizenship or place of organization<br>**P7** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**10237714.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**10237714.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**10237714.00** | Aggregate amount beneficially owned by each reporting person<br>**10237714.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.99%** | Percent of class represented by amount in Row (11)<br>**9.99%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** The reported share amounts consist of (i) 3,617,354 shares of Common Stock and (ii) 6,620,360 shares of Common Stock underlying Pre-Funded Warrants. Exercisability of the Pre-Funded Warrants is subject to the 9.99% Beneficial Ownership Limitation. The percentage set forth in Row 13 gives effect to such Beneficial Ownership Limitation, but the number of shares reported in Rows 8, 10 and 12 includes the full number of shares of Common Stock underlying the Pre-Funded Warrants and does not give effect to the Beneficial Ownership Limitation.  As such, some of the Pre-Funded Warrants are not presently exercisable due to the Beneficial Ownership Limitation, and the actual number of shares of Common Stock beneficially owned by the Reporting Persons is less than the number of shares of Common Stock of the Issuer reported herein.

| **CUSIP No.** | **929033207** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Forbion Growth III Management B.V.** | Name of reporting person<br>**Forbion Growth III Management B.V.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**P7** | Citizenship or place of organization<br>**P7** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**10237714.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**10237714.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**10237714.00** | Aggregate amount beneficially owned by each reporting person<br>**10237714.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.99%** | Percent of class represented by amount in Row (11)<br>**9.99%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** The reported share amounts consist of (i) 3,617,354 shares of Common Stock and (ii) 6,620,360 shares of Common Stock underlying Pre-Funded Warrants.  Exercisability of the Pre-Funded Warrants is subject to the 9.99% Beneficial Ownership Limitation. The percentage set forth in Row 13 gives effect to such Beneficial Ownership Limitation, but the number of shares reported in Rows 8, 10 and 12 includes the full number of shares of Common Stock underlying the Pre-Funded Warrants and does not give effect to the Beneficial Ownership Limitation.  As such, some of the Pre-Funded Warrants are not presently exercisable due to the Beneficial Ownership Limitation, and the actual number of shares of Common Stock beneficially owned by the Reporting Persons is less than the number of shares of Common Stock of the Issuer reported herein.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.0001 par value per share

**(b) Name of Issuer:**
VOR BIOPHARMA INC.

**(c) Address of Issuer's Principal Executive Offices:**
500 BOYLSTON STREET, SUITE 1350, BOSTON, MA, 02116

**Item 4. Purpose of Transaction**

The Reporting Persons acquired their shares of Common Stock as an investment in the ordinary course of business.

On December 18, 2025, Wouter Joustra, a General Partner at Forbion Capital, was appointed to the Issuer's board of directors. The Reporting Persons, either directly or indirectly through Mr. Joustra, may engage in discussions from time to time with the Issuer's board of directors, the Issuer's management or the Issuer's other stockholders. These discussions may be with respect to (i) acquiring or disposing of the shares or other securities of the Issuer; (ii) maintaining or changing the Issuer's business, operations, governance, management, strategy or capitalization; or (iii) implementing transactions that may relate to or may result in any matter set forth in paragraphs (a) through (j) of Item 4 of Schedule 13D. Additionally, the Reporting Persons may acquire additional securities through open market transactions, privately negotiated transactions or other methods.

In connection with the foregoing, and as may be appropriate from time to time, each of the Reporting Persons may consider the feasibility and advisability of various alternative courses of action with respect to their investment in the Issuer, including, without limitation: (a) the acquisition or disposition by the Reporting Persons of the shares, including through derivative transactions which may include security-based swaps and short sales; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) changes in the present board of directors or management of the Issuer; (e) a material change in the present capitalization or dividend policy of the Issuer; (f) other material changes in the Issuer's business or corporate structure; (g) changes in the Issuer's articles of incorporation or bylaws or other actions that may impede the acquisition of control of the Issuer by any person; (h) causing any class of the Issuer's securities to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) causing a class of equity securities of the Issuer to become eligible for termination of registration pursuant to Section 12 of the Exchange Act; or (j) any action similar to those enumerated above. Except as described in Item 6 and this Item 4 and any plans or proposals that may from time to time be discussed or considered by the directors of the Issuer, including Mr. Joustra in his fiduciary capacity as a director of the Issuer, the Reporting Persons do not currently have any plans or proposals that relate to or would result in any of the actions specified in clause (a) through (j) of this paragraph.

The Reporting Persons intend to review their investment in the Issuer from time to time on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's stock in particular, as well as other developments.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The information set forth in rows 7 through 13 of the cover pages to this Schedule 13D is incorporated by reference. ForGrowth III is the direct holder of (i) 3,617,354 shares of Common Stock and (ii) 6,620,360 shares of Common Stock underlying Warrants. Forbion Growth III COOP, the sole shareholder of ForGrowth III, and Forbion Growth III, as director of each of ForGrowth III and Forbion Growth III COOP, may be deemed to have voting and investment power over the shares beneficially owned by ForGrowth III.

**(b)**
The Reporting Persons may be deemed to beneficially own 9.99% of the outstanding Common Stock of the Issuer after giving effect to the Beneficial Ownership Limitation described in Item 3.

**(c)**
Information with respect to all transactions in the shares of Common Stock beneficially owned by the Reporting Persons that were effected during the past sixty days is set forth in Item 3 and incorporated herein by reference.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The information contained in Items 3 and 4 of the Schedule 13D is incorporated by reference into this Item 6.

June 2025 Registration Rights Agreement

On June 25, 2025, the Issuer entered into a registration rights agreement (the "June 2025 Registration Rights Agreement") with certain investors, including ForGrowth III. Pursuant to the terms of the June 2025 Registration Rights Agreement, the Issuer agreed to file a registration statement to register for resale the shares of Common Stock underlying Pre-Funded Warrants within 30 days of the approval by the Issuer's stockholders of the issuance of such shares and an amendment to the Issuer's certificate of incorporation that has the effect of increasing the number of authorized but unissued shares of common stock, and to use reasonable best efforts to have the registration statement declared effective at the earliest possible date but no later than the earlier of (a) the 75th calendar day following the initial filing date of the registration statement if the SEC notifies the Issuer that it will review the registration statement and (b) the fifth business day after the date the SEC notifies the Issuer that the registration statement will not be reviewed or be subject to further review. The June 2025 Registration Rights Agreement provides for liquidated damages payable to the Investors if the Issuer fails to meet certain filing or effectiveness deadlines, subject to specified caps. The June 2025 Registration Rights Agreement includes customary provisions regarding payment of fees and expenses and indemnification.

The foregoing description of the June 2025 Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the June 2025 Registration Rights Agreement, a copy of which is filed as Exhibit 99.5 hereto and incorporated by reference herein.

December 2025 Registration Rights Agreement

On December 15, 2025, the Issuer entered into a registration rights agreement (the "December 2025 Registration Rights Agreement") with the December 2025 PIPE Investors, pursuant to which the Issuer agreed to register for resale the December 2025 PIPE Shares held by the December 2025 PIPE Investors (the "December 2025 Registrable Securities"). Under the December 2025 Registration Rights Agreement, the Issuer has agreed to file a registration statement (the "December 2025 Registration Statement") covering the resale of the December 2025 Registrable Securities within 45 days of the closing date of the December 2025 Private Placement and to use its reasonable best efforts to cause such registration statement declared effective as soon as possible, but no later than 75 days after the initial filing date of the December 2025 Registration Statement, subject to extension under the terms of the December 2025 Registration Rights Agreement. The December 2025 Registration Rights Agreement provides for liquidated damages payable to the Investors if the Issuer fails to meet certain filing or effectiveness deadlines, subject to specified caps. The December 2025 Registration Rights Agreement includes customary provisions regarding payment of fees and expenses and indemnification.

The foregoing description of the December 2025 Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the December 2025 Registration Rights Agreement, a copy of which is filed as Exhibit 99.6 hereto and incorporated by reference herein.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** ForGrowth III PA B.V.

**Signature:** /s/ M. van Osch and /s/ G.J. Mulder

**Name/Title:** M. van Osch and G.J. Mulder, Directors of its Director

**Date:** 12/23/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Forbion Growth Opportunities Fund III Cooperatief U.A.

**Signature:** /s/ M. van Osch and /s/ G.J. Mulder

**Name/Title:** M. van Osch and G.J. Mulder, Directors of its Director

**Date:** 12/23/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Forbion Growth III Management B.V.

**Signature:** /s/ M. van Osch and /s/ G.J. Mulder

**Name/Title:** M. van Osch and G.J. Mulder, Directors

**Date:** 12/23/2025